TMDI VS BLPH Stock Comparison

Performance

TMDI
10/100

TMDI returned -73.08% in the last 12 months. Based on the other stocks in it's sector with an average return of -23.10%, it's performance is below average giving it a grade of 10 of 100.

BLPH
10/100

BLPH returned -90.60% in the last 12 months. Based on SPY's performance of -11.83%, its performance is below average giving it a score of 10 of 100.

Sentiment

TMDI
65/100

TMDI had a bullish sentiment score of 64.63% across Twitter and StockTwits over the last 12 months. It had an average of 17.43 posts, 15.89 comments, and 57.00 likes per day.

BLPH

"Sentiment" not found for BLPH

Technicals

TMDI
14/100

TMDI receieves a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

BLPH
11/100

BLPH receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

TMDI
16/100

TMDI has missed earnings 3 times in the last 20 quarters.

BLPH
36/100

BLPH has missed earnings 3 times in the last 20 quarters.

Volatility

TMDI
55/100

TMDI has had a higher than average amount of volatility over the last 12 months giving it a grade of 54 of 100.

BLPH
57/100

BLPH has had a higher than average amount of volatility over the last 12 months giving it a score of 57 of 100.

Analyst Price Targets

TMDI

"Analyst Price Targets" not found for TMDI

BLPH
75/100

1 analysts offer 12-month price targets for BLPH. Together, they have an average target of 19, the most optimistic target put BLPH at 19 within 12-months and the most pessimistic has BLPH at 19. These analyst ratings are from our partners at Financial Modeling Prep and Alpha Vantage.

Profit

TMDI

"Profit" not found for TMDI

BLPH
10/100

Out of the last 20 quarters, BLPH has had 2 profitable quarters and has increased their profits year over year on 1 of them.

All score calculations are broken down here to help you make more informed investing decisions

Titan Medical Inc. Ordinary Shares Summary

Nasdaq / TMDI

Healthcare

Medical Devices

Titan Medical Inc., a medical technology company, focuses on the development and commercialization of robotic assisted surgical technologies for application in minimally invasive surgery. It is developing the Enos system, a robotic single access surgical system that includes a surgeon-controlled patient cart comprising a 3D high-definition vision system and multi-articulating instruments for performing surgical procedures; and a surgeon workstation that provides the surgeon with ergonomic interface to the patient cart and a 3D endoscopic view inside the patient's body during surgical procedures. The company is headquartered in Toronto, Canada.

Bellerophon Therapeutics, Inc. Summary

Nasdaq / BLPH

Healthcare

Biotechnology

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Power up your portfolio